| |  Online-Ressource |
|---|
| Verfasst von: | Korell, Felix [VerfasserIn]  |
|---|
| | Schubert, Maria-Luisa [VerfasserIn] |
|---|
| | Sauer, Tim [VerfasserIn] |
|---|
| | Schmitt, Anita [VerfasserIn] |
|---|
| | Derigs, Patrick [VerfasserIn] |
|---|
| | Weber, Tim [VerfasserIn] |
|---|
| | Schnitzler, Paul [VerfasserIn] |
|---|
| | Müller-Tidow, Carsten [VerfasserIn] |
|---|
| | Dreger, Peter [VerfasserIn] |
|---|
| | Schmitt, Michael [VerfasserIn] |
|---|
| Titel: | Infection complications after lymphodepletion and dosing of chimeric antigen receptor T (CAR-T) cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia or B cell non-Hodgkin lymphoma |
|---|
| Verf.angabe: | Felix Korell, Maria-Luisa Schubert, Tim Sauer, Anita Schmitt, Patrick Derigs, Tim Frederik Weber, Paul Schnitzler, Carsten Müller-Tidow, Peter Dreger and Michael Schmitt |
|---|
| E-Jahr: | 2021 |
|---|
| Jahr: | 2 April 2021 |
|---|
| Umfang: | 12 S. |
|---|
| Fussnoten: | Gesehen am 18.02.2022 |
|---|
| Titel Quelle: | Enthalten in: Cancers |
|---|
| Ort Quelle: | Basel : MDPI, 2009 |
|---|
| Jahr Quelle: | 2021 |
|---|
| Band/Heft Quelle: | 13(2021), 7, Artikel-ID 1684, Seite 1-12 |
|---|
| ISSN Quelle: | 2072-6694 |
|---|
| Abstract: | Chimeric antigen receptor T (CAR-T) cell therapy has proven to be very effective in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). However, infections—related either due to lymphodepletion or the CAR-T cell therapy itself—can result in severe and potentially life-threatening complications, while side effects such as cytokine release syndrome (CRS) might complicate differential diagnosis. Sixty-seven dosings of CAR-T cells in sixty adult patients with NHL (85%) and ALL (15%) receiving CAR-T cell therapy were assessed for infectious complications. Almost two-thirds of patients (61%) developed fever following lymphodepletion and CAR-T cell dosing. Microbiological or radiological findings were observed in 25% of all cases (bacterial 12%, viral 5%, fungal 8%). Inpatient infections were associated with more lines of therapy and more severe CRS. However, overall serious complications were rare after CAR-T therapy, with one patient dying of infection. Pathogen detection after inpatient stay was infrequent and mostly occurred in the first 90 days after dosing. Infections in CAR-T cell treated patents are common. Fast and suitable identification and treatment are crucial in these heavily pretreated and immunocompromised patients. In most cases infectious complications are manageable. Nonetheless, standardized anti-infective prophylaxis and supportive therapy are mandatory to reduce morbidity and mortality in CAR-T cell therapy. |
|---|
| DOI: | doi:10.3390/cancers13071684 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.3390/cancers13071684 |
|---|
| | Volltext: https://www.mdpi.com/2072-6694/13/7/1684 |
|---|
| | DOI: https://doi.org/10.3390/cancers13071684 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | CAR-T cell |
|---|
| | cytokine release syndrome |
|---|
| | infection |
|---|
| | lymphodepletion |
|---|
| K10plus-PPN: | 1790093759 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Infection complications after lymphodepletion and dosing of chimeric antigen receptor T (CAR-T) cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia or B cell non-Hodgkin lymphoma / Korell, Felix [VerfasserIn]; 2 April 2021 (Online-Ressource)
